Lexaria Bioscience Corp.
LEXX
$1.35
$0.032.27%
| 11/30/2024 | 08/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 118.93% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 118.93% | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 115.71% | 0.00% | |||
| SG&A Expenses | -27.20% | 0.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.95% | 22.02% | |||
| Operating Income | -25.43% | -23.08% | |||
| Income Before Tax | -23.78% | -22.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.78% | -22.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 61.11% | -30.77% | |||
| Net Income | -23.75% | -22.62% | |||
| EBIT | -25.43% | -23.08% | |||
| EBITDA | -24.83% | -23.21% | |||
| EPS Basic | -16.61% | -8.16% | |||
| Normalized Basic EPS | -18.61% | -8.29% | |||
| EPS Diluted | -16.61% | -8.16% | |||
| Normalized Diluted EPS | -18.61% | -8.29% | |||
| Average Basic Shares Outstanding | 6.09% | 13.40% | |||
| Average Diluted Shares Outstanding | 6.09% | 13.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
